<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03909451</url>
  </required_header>
  <id_info>
    <org_study_id>TDR15349</org_study_id>
    <secondary_id>U1111-1199-6171</secondary_id>
    <nct_id>NCT03909451</nct_id>
  </id_info>
  <brief_title>Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Determine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered Sotagliflozin in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the safety and tolerability of sotagliflozin after a multiple oral dose
      administration in Chinese healthy subjects.

      Secondary Objectives:

        -  To assess the pharmacokinetic (PK) parameters of sotagliflozin after a multiple oral
           dose administration in Chinese healthy subjects.

        -  To assess the pharmacodynamics (PD) parameters of absolute urinary glucose excretion
           after a multiple oral dose administration in Chinese healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration per subject will be up to 41 days and will consist of a screening period
      of up to 28 days, a dosing period of 8 days, and a follow up visit 5 days after last dosing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2019</start_date>
  <completion_date type="Actual">August 19, 2019</completion_date>
  <primary_completion_date type="Actual">August 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Up to 41 days</time_frame>
    <description>Proportion of patients who experienced adverse events/treatment-emergent AEs (TEAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Maximum plasma concentration (Cmax)</measure>
    <time_frame>On Day 1 and from Day 8 to Day 13</time_frame>
    <description>Sotagliflozin and Sotagliflozin-O-glucuronide: Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Area under curve from 0 to 24 hours (AUCtau)</measure>
    <time_frame>On Day 1 and Day 8</time_frame>
    <description>Sotagliflozin and Sotagliflozin-O-glucuronide: Area under curve from 0 to 24 hours (AUCtau) of sotagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Area under the concentration-time curve (AUC)</measure>
    <time_frame>From Day 8 to Day 13</time_frame>
    <description>Sotagliflozin and Sotagliflozin-O-glucuronide: Area under the concentration-time curve from 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter: urinary glucose excretion (UGE)</measure>
    <time_frame>On Day 1 and Day 8</time_frame>
    <description>Total 24-hour urinary glucose excretion (UGE) after dose with sotagliflozin</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sotagliflozin dose 1, once daily for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sotagliflozin dose 2, once daily for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, once daily for 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotagliflozin (SAR439954)</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Male or female subjects, between 18 and 45 years of age, inclusive.

          -  Body weight between 50.0 and 95.0 kg, inclusive, for male or female subjects; body
             mass index between 18.5 and 27.9 kg/m2, inclusive.

          -  Certified as healthy by a comprehensive clinical assessment (detailed medical history
             and complete physical examination), vital signs, electrocardiogram, and clinical
             laboratory parameters.

        Exclusion criteria:

          -  Any history or presence of clinically relevant illness at screening, which could
             interfere with the objectives of the study or the safety of the subject's
             participation.

          -  Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting
             only: more than twice a month).

          -  Blood donation any volume, within 2 months before inclusion.

          -  Symptomatic postural hypotension.

          -  Presence or history of drug hypersensitivity, or allergic disease diagnosed and
             treated by a physician.

          -  History or presence of drug or alcohol abuse.

          -  Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during
             the study.

          -  If female, pregnancy, breast-feeding.

          -  Any medication (including St John's Wort) within 14 days before inclusion or within 5
             times the elimination half-life or pharmacodynamic half-life of the medication; any
             vaccination within the last 28 days and any biologics (antibody or its derivatives)
             given within 4 months before inclusion.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 1560001</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

